Further evidence for the potential of AZD9291 in NSCLC presented at WCLC
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
List view / Grid view
News
First patient enrolled in Phase 4 AUGUSTUS trial of Eliquis
9 September 2015 | By Victoria White
The trial will evaluate the safety of Eliquis versus warfarin or other vitamin K antagonists in patients with nonvalvular atrial fibrillation and a recent acute coronary syndrome or undergoing percutaneous coronary intervention...
Phase III data confirms efficacy of perampanel and rufinamide
9 September 2015 | By Victoria White
Data presented at the International Epilepsy Congress in Istanbul show Eisai’s perampanel may significantly reduce seizure frequency, both in patients with primary generalised tonic-clonic (PGTC) seizures and partial epilepsy...
Results from the SUMMIT COPD CV survival study announced
9 September 2015 | By Victoria White
For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant...
EC grants marketing authorisation for Raxone in Leber’s Hereditary Optic Neuropathy
9 September 2015 | By Victoria White
Raxone is the first approved treatment for Leber’s Hereditary Optic Neuropathy, and for a mitochondrial disease, in the EU...
AstraZeneca in bioinformatics collaboration with University of Manchester
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
New analytical solution brings nanoscale chemical imaging to new levels of ease and automation.
8 September 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in Raman spectroscopy solutions, announces an innovative solution that addresses the challenges of TERS imaging...
First patient enrolled in Phase 3 study of aducanumab in Alzheimer’s
8 September 2015 | By Victoria White
Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...
Twice-daily cough syrup Tuzistra XR launched in the US
8 September 2015 | By Victoria White
Tuzistra XR is the only codeine-based extended-release cough cold syrup available to patients and physicians in the United States...
NSCLC treatment market value to approach $11 billion by 2021
8 September 2015 | By Victoria White
This increase will be driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, says GBI Research...
First patient dosed in Phase I trial of universal HIV vaccine Pennvax-GP
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
Phenomenex and Tecan to co-market automated sample preparation solutions
8 September 2015 | By Tecan
Phenomenex, Inc. and the Tecan Group (SIX Swiss Exchange: TECN) today announced a collaboration to co-market automated solid phase extraction (SPE) sample preparation solutions...
Sanifit raises €36.6 million to advance SNF472
8 September 2015 | By Victoria White
SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with end stage renal disease...
Opdivo demonstrates sustained survival results in squamous NSCLC
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
Responsible Person training supported by MHRA Inspectorate
7 September 2015 | By Victoria White
The MHRA has said it is now seeing greater appreciation among pharmaceutical sector companies of the skills required for the essential Responsible Person role...
